OC
CSBR icon

Oppenheimer & Co’s Champions Oncology CSBR Stock Holding History

Oppenheimer & Co’s Portfolio CSBR Stock Details CSBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-19,715
Closed -$344K – 1265
2018
Q3 		$344K Buy
+19,715
New +$176K 0.01% 1012

Other funds holding CSBR

BPI
Battery Partners IX Boston, Massachusetts $22.4M AUM 27.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Cadence Capital Management Boston, Massachusetts $415M AUM 11.01% 1-Year Est. Return

Oppenheimer & Co's CSBR Position: Q4 2018 in Review

Oppenheimer & Co sold out of Champions Oncology (CSBR) in Q4 2018, closing a stake of 19,715 shares — an estimated $344K sold.

Oppenheimer & Co first reported a position in CSBR in Q3 2018 and held it in 1 quarter. The position peaked at $344K in Q3 2018. 45 funds tracked by Wall St. Rank hold CSBR as of Q4 2018.

  • Oppenheimer & Co reported no remaining Champions Oncology position as of Q4 2018 after selling out during the quarter.
  • Oppenheimer & Co sold 19,715 Champions Oncology shares in Q4 2018, an estimated $344K.
  • Oppenheimer & Co first reported a position in Champions Oncology in Q3 2018 and held it in 1 quarter.
  • Oppenheimer & Co's Champions Oncology position peaked at $344K in Q3 2018.
  • 45 funds tracked by Wall St. Rank held Champions Oncology as of Q4 2018.

Based on Oppenheimer & Co's 13F filing for Q4 2018, filed 29 Jan 2019.